Today, Acorda Therapeutics Inc. (ACOR) Receives $39.40 Consensus PT from Analysts

Today, Acorda Therapeutics Inc. (ACOR) Receives $39.40 Consensus PT from Analysts

Acorda Therapeutics Inc. (NASDAQ:ACOR) has been assigned an average rating of “Hold” from the nine brokerages that are presently covering the company. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $39.40.

Several equities research analysts recently weighed in on ACOR shares. Leerink Swann started coverage on Acorda Therapeutics in a report on Tuesday, October 4th. They set a “market perform” rating and a $25.00 price objective on the stock. TheStreet downgraded Acorda Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 28th. Stifel Nicolaus reissued a “buy” rating on shares of Acorda Therapeutics in a report on Thursday, August 25th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Acorda Therapeutics in a report on Thursday, August 25th. Finally, Cowen and Company reissued an “outperform” rating and set a $65.00 price objective on shares of Acorda Therapeutics in a report on Thursday, August 25th.

Shares of Acorda Therapeutics (NASDAQ:ACOR) opened at 19.63 on Wednesday. The company’s market capitalization is $904.75 million. Acorda Therapeutics has a one year low of $18.78 and a one year high of $43.63. The firm has a 50 day moving average price of $23.27 and a 200 day moving average price of $25.57.

Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Thursday, July 28th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by $0.11. Acorda Therapeutics had a negative net margin of 1.08% and a positive return on equity of 1.00%. The firm had revenue of $127.45 million for the quarter, compared to analyst estimates of $128.33 million. During the same period last year, the business earned $0.31 EPS. The company’s revenue was up 12.1% compared to the same quarter last year. On average, equities research analysts predict that Acorda Therapeutics will post $0.47 EPS for the current fiscal year.

In other news, insider Jane Wasman sold 3,750 shares of the business’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $20.78, for a total value of $77,925.00. Following the transaction, the insider now directly owns 105,021 shares of the company’s stock, valued at approximately $2,182,336.38. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 8.00% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Louisiana State Employees Retirement System increased its position in shares of Acorda Therapeutics by 0.5% in the second quarter. Louisiana State Employees Retirement System now owns 20,400 shares of the biopharmaceutical company’s stock worth $520,000 after buying an additional 100 shares in the last quarter. PineBridge Investments L.P. increased its position in shares of Acorda Therapeutics by 4.5% in the second quarter. PineBridge Investments L.P. now owns 5,842 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 253 shares in the last quarter. Texas Permanent School Fund increased its position in shares of Acorda Therapeutics by 1.0% in the first quarter. Texas Permanent School Fund now owns 36,077 shares of the biopharmaceutical company’s stock worth $954,000 after buying an additional 366 shares in the last quarter. Arizona State Retirement System increased its position in shares of Acorda Therapeutics by 1.7% in the second quarter. Arizona State Retirement System now owns 23,905 shares of the biopharmaceutical company’s stock worth $610,000 after buying an additional 400 shares in the last quarter. Finally, Whittier Trust Co. increased its position in shares of Acorda Therapeutics by 1.2% in the second quarter. Whittier Trust Co. now owns 33,511 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 404 shares in the last quarter.

Related posts

Leave a Comment